within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BK01_Dapagliflozin;
model Dapagliflozin 
   extends Pharmacolibrary.Drugs.ATC.A.A10BK01;

  annotation(Documentation(
    info ="<html><body><p>Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor approved for the treatment of type 2 diabetes mellitus. It lowers blood glucose by promoting urinary glucose excretion and has also been approved to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers (both male and female) after single oral dose under fasting conditions.</p><h4>References</h4><ol><li><p>Kasichayanula, S, et al., &amp; Boulton, DW (2014). Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. <i>Clinical pharmacokinetics</i> 53(1) 17–27. DOI:<a href=&quot;https://doi.org/10.1007/s40262-013-0104-3&quot;>10.1007/s40262-013-0104-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24105299/&quot;>https://pubmed.ncbi.nlm.nih.gov/24105299</a></p></li><li><p>Dhillon, S (2019). Dapagliflozin: A Review in Type 2 Diabetes. <i>Drugs</i> 79(10) 1135–1146. DOI:<a href=&quot;https://doi.org/10.1007/s40265-019-01148-3&quot;>10.1007/s40265-019-01148-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31236801/&quot;>https://pubmed.ncbi.nlm.nih.gov/31236801</a></p></li><li><p>Tirucherai, GS, et al., &amp; Boulton, DW (2016). Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitus. <i>Diabetes, obesity &amp; metabolism</i> 18(7) 678–684. DOI:<a href=&quot;https://doi.org/10.1111/dom.12638&quot;>10.1111/dom.12638</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27291448/&quot;>https://pubmed.ncbi.nlm.nih.gov/27291448</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Dapagliflozin;
